108 0 Kommentare BioCardia Signs Agreement with Leading Japanese Biotechnology Company for Catheter Biotherapeutic Delivery Product Candidates

Second Biotherapeutic Partnership of 2021

SAN CARLOS, Calif., April 26, 2021 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], today announced that it has entered into an agreement with a leading Japanese biotechnology company related to BioCardia Helix catheter biotherapeutic delivery product candidates. Under the terms of the agreement, BioCardia will receive $500,000, a portion of which is creditable for biotherapeutic delivery products and support services. The agreement has a one-year term with an option to negotiate for a non-exclusive world-wide license to BioCardia Helix catheter biotherapeutic delivery product candidates for certain cell types for cardiac indications.

“Our collaboration with this leading Japanese biotechnology company further validates our core Helix biotherapeutic delivery technology as the leading delivery platform for local cell, gene and protein-based therapy to the heart. This is the first partnered program that is anticipated to benefit from one of our newer delivery catheter technologies and our goal is to continue this collaboration through clinical development to commercialization by this new partner,” said BioCardia CEO Peter Altman, Ph.D. “Recent publications have demonstrated our leading Helix delivery platforms best in class efficiency^(1), and clinical performance⁽²^,3⁾. These Helix system advantages are believed to underlie our recently reported CardiAMP cell therapy clinical results in heart failure⁽⁴⁾. We look forward to bringing all of our experience and delivery technologies to bear to help advance this new partner’s important therapeutic development efforts.”

Mitsutake Y, Pyun WB, Rouy D, et al. Improvement of local cell delivery using Helix transendocardial delivery catheter in a porcine heart. Int Heart J. (2017).
Raval AN, Pepine CJ. Clinical safety profile of transendocardial catheter injection systems: A plea for uniform reporting. Cardiovascular Revascularization Medicine (2020).
Duckers, HJ, Ravel AN, Pepine, CJ, Johnston, PV, Traverse JH, Emery, J, Miller, L, Abraham, WT, Altman, PA. Performance of Helix transendocardial biotherapeutic delivery system after 300 cases. Presented at the Annual Meeting of Transcatheter Cardiovascular Therapeutics, September 24, 2018.
Raval AN, Johnston PV, Duckers HJ, et al. Point of care, bone marrow mononuclear cell therapy in ischemic heart failure patients personalized for cell potency: 12-month feasibility results from CardiAMP heart failure roll-in cohort, Int J. Cardiology (2020).